Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis and the risk of bleeding. The full consensus document comprehensively reviews the published evidence and presents a consensus statement on a 'best practice' antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients. This executive summary highlights the main recommendations from the consensus document.
Lip
Gregory Y H
GY
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK. g.y.h.lip@bham.ac.uk
Huber
Kurt
K
Andreotti
Felicita
F
Arnesen
Harald
H
Airaksinen
Juhani K
JK
Cuisset
Thomas
T
Kirchhof
Paulus
P
Marín
Francisco
F
D054058:Acute Coronary Syndrome / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D005060:Europe; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D012307:Risk Factors; D015607:Stents; D020521:Stroke / Q000517:prevention & control; D013923:Thromboembolism / Q000517:prevention & control
D005343:Fibrinolytic Agents